---
title: "Grifols doses first patient in Phase 3 SIGMA trial of Gamunex-C in secondary immunodeficiency"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292902989.md"
description: "Grifols has dosed the first patient in the Phase 3 SIGMA trial, which evaluates GAMUNEX-C combined with standard care to prevent infections in patients with secondary immunodeficiency associated with hematologic cancers. Additionally, Grifols initiated the XPERT trial to assess whether subcutaneous XEMBIFY is non-inferior to GAMUNEX-C in treating CIDP, aiming for label expansion."
datetime: "2026-07-16T12:08:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292902989.md)
  - [en](https://longbridge.com/en/news/292902989.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292902989.md)
generator: "portal-rs"
---

# Grifols doses first patient in Phase 3 SIGMA trial of Gamunex-C in secondary immunodeficiency

-   Grifols dosed first patients in two Phase 3 trials aimed at expanding U.S. labels for immunoglobulin therapies GAMUNEX-C, XEMBIFY. \* SIGMA trial tests GAMUNEX-C with standard care to prevent infections in secondary immunodeficiency tied to hematologic cancers. \* XPERT trial evaluates whether subcutaneous XEMBIFY is non-inferior to GAMUNEX-C in CIDP, supporting a potential label expansion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160800PRIMZONEFULLFEED9763208) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [GRFS.US](https://longbridge.com/en/quote/GRFS.US.md)

## Related News & Research

- [DNTH: Multiple clinical milestones and strong financials position the pipeline for major neuromuscular market impact](https://longbridge.com/en/news/298507185.md)
- [ARGX: Strong growth in MG and CIDP, pipeline expansion, and innovation drive long-term immunology leadership](https://longbridge.com/en/news/298340062.md)
- [HALO: Subcutaneous delivery platforms drive record growth, new deals, and expanding royalty streams](https://longbridge.com/en/news/298503232.md)
- [KARD: Late-stage cardiovascular pipeline advances with adaptive trials and digital health integration](https://longbridge.com/en/news/298494379.md)
- [AIM ImmunoTech advances Phase 2 DURIPANC trial of Ampligen plus AstraZeneca’s Imfinzi in pancreatic cancer](https://longbridge.com/en/news/298463441.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**